{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:30:52Z","timestamp":1755221452649,"version":"3.43.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006109","name":"Vedeck\u00e1 Grantov\u00e1 Agent\u00fara M\u0160VVa\u0160 SR a SAV","doi-asserted-by":"publisher","award":["VEGA 2\/0116\/22"],"award-info":[{"award-number":["VEGA 2\/0116\/22"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["09I03-03-V04-00283"],"award-info":[{"award-number":["09I03-03-V04-00283"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>\n              <jats:italic>Silybum marianum<\/jats:italic> (milk thistle) is a plant for centuries well known for its hepatoprotective effects. The extract from seeds, silymarin, and its major compound, silibinin, are well studied for their hepatoprotective and antifibrotic effects. The role of other minor compounds, such as isosilybin B, remains underexplored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study aimed to compare the cytotoxic and antifibrotic properties of IB with those of silibinin and silymarin in vitro. It focuses on evaluating the cytotoxic effect of these substances on tumor and non-tumor liver cells. Moreover, antifibrotic potential of the three substances was determined in healthy liver cells treated with TGF-\u03b21.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Isosilybin B exhibits greater cytotoxicity toward liver cancer cells while being less toxic to non-tumor hepatocytes compared to silibinin. At non-toxic concentrations, isosilybin B induced cell cycle arrest at the G1 phase in two types of liver cancer cells. In contrast, it did not impact the cell cycle of non-tumor cells under the same experimental conditions. In the model of liver fibrosis in vitro induced by TGF-\u03b21, isosilybin B reduced the mRNA expression of pro-fibrotic genes as well as ALT level in the culture medium more effectively than silibinin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Obtained results suggest that isosilybin B represents a promising anticancer agent for the treatment of liver cancer. Moreover, its anti-fibrotic properties emphasize its potential for treatment of many other liver diseases, which underline the strong potential of isosilybin B in future anticancer and antifibrotic therapeutic strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12672-025-03380-8","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T07:35:04Z","timestamp":1754638504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Isosilybin B: a potential novel therapeutic agent with hepatoprotective, anticancer and antifibrotic properties"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7330-6655","authenticated-orcid":false,"given":"Michal","family":"Selc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8251-5328","authenticated-orcid":false,"given":"Kristina","family":"Jakic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radka","family":"Macova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9548-6602","authenticated-orcid":false,"given":"Andrea","family":"Babelova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"3380_CR1","doi-asserted-by":"publisher","unstructured":"Ray PP, Islam MA, Islam MS, Han A, Geng P, Aziz MA, Mamun A, Al. A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment. Front Pharmacol. 2024;15. https:\/\/doi.org\/10.3389\/fphar.2024.1349745.","DOI":"10.3389\/fphar.2024.1349745"},{"key":"3380_CR2","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.2147\/DDDT.S483140","volume":"18","author":"M Selc","year":"2024","unstructured":"Selc M, Macova R, Babelova A. Novel strategies enhancing bioavailability and therapeutical potential of Silibinin for treatment of liver disorders. Drug Des Devel Ther. 2024;18:4629\u201359. https:\/\/doi.org\/10.2147\/DDDT.S483140.","journal-title":"Drug Des Devel Ther"},{"key":"3380_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/CAAC.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/CAAC.21834.","journal-title":"CA Cancer J Clin"},{"key":"3380_CR4","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2174\/138920112802273353","volume":"13","author":"U Mengs","year":"2012","unstructured":"Mengs U, Torsten Pohl R-, Mitchell T, Legalon\u00ae SIL. The antidote of choice in patients with acute hepatotoxicity from amatoxin poisoning. Curr Pharm Biotechnol. 2012;13:1964\u201370. https:\/\/doi.org\/10.2174\/138920112802273353.","journal-title":"Curr Pharm Biotechnol"},{"key":"3380_CR5","first-page":"2510","volume":"7","author":"M Malaguarnera","year":"2015","unstructured":"Malaguarnera M, Motta M, Vacante M, Malaguarnera G, Caraci F, Nunnari G, Gagliano C, Greco C, Chisari G, Drago F, Bertino G. Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon \u03b1 and ribavirin. Am J Transl Res. 2015;7:2510\u20138. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26807195.","journal-title":"Am J Transl Res"},{"key":"3380_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/1534735413490798","volume":"13","author":"AB Siegel","year":"2014","unstructured":"Siegel AB, Narayan R, Rodriguez R, Goyal A, Jacobson, DrPH JS, Kelly K, Ladas E, Lunghofer PJ, Hansen RJ, Gustafson DL, Flaig TW, Yann Tsai W, Wu DPH, Lee V, Greenlee H. A phase I Dose-Finding study of Silybin phosphatidylcholine (Milk Thistle) in patients with advanced hepatocellular carcinoma. Integr Cancer Ther. 2014;13:46\u201353. https:\/\/doi.org\/10.1177\/1534735413490798.","journal-title":"Integr Cancer Ther"},{"key":"3380_CR7","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.freeradbiomed.2012.02.008","volume":"52","author":"C Loguercio","year":"2012","unstructured":"Loguercio C, Andreone P, Brisc C, Brisc MC, Bugianesi E, Chiaramonte M, Cursaro C, Danila M, de Sio I, Floreani A, Freni MA, Grieco A, Groppo M, Lazzari R, Lobello S, Lorefice E, Margotti M, Miele L, Milani S, Okolicsanyi L, Palasciano G, Portincasa P, Saltarelli P, Smedile A, Somalvico F, Spadaro A, Sporea I, Sorrentino P, Vecchione R, Tuccillo C, Blanco CDV, Federico A. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic Biol Med. 2012;52:1658\u201365. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2012.02.008.","journal-title":"Free Radic Biol Med"},{"key":"3380_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/169216","volume":"2014","author":"P Stiuso","year":"2014","unstructured":"Stiuso P, Scognamiglio I, Murolo M, Ferranti P, De Simone C, Rizzo MR, Tuccillo C, Caraglia M, Loguercio C, Federico A. Serum oxidative stress markers and lipidomic profile to detect NASH patients responsive to an antioxidant treatment: A pilot study. Oxid Med Cell Longev. 2014;2014:1\u20138. https:\/\/doi.org\/10.1155\/2014\/169216.","journal-title":"Oxid Med Cell Longev"},{"key":"3380_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/0192623310394211","volume":"39","author":"JK Dunnick","year":"2011","unstructured":"Dunnick JK, Singh B, Nyska A, Peckham J, Kissling GE, Sanders JM. Investigating the potential for toxicity from Long-Term use of the herbal products, goldenseal and milk Thistle. Toxicol Pathol. 2011;39:398\u2013409. https:\/\/doi.org\/10.1177\/0192623310394211.","journal-title":"Toxicol Pathol"},{"key":"3380_CR10","doi-asserted-by":"publisher","first-page":"11118","DOI":"10.1038\/s41598-019-47250-0","volume":"9","author":"M Fenclova","year":"2019","unstructured":"Fenclova M, Novakova A, Viktorova J, Jonatova P, Dzuman Z, Ruml T, Kren V, Hajslova J, Vitek L, Stranska-Zachariasova M. Poor chemical and Microbiological quality of the commercial milk thistle-based dietary supplements May account for their reported unsatisfactory and non-reproducible clinical outcomes. Sci Rep. 2019;9:11118. https:\/\/doi.org\/10.1038\/s41598-019-47250-0.","journal-title":"Sci Rep"},{"key":"3380_CR11","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1073\/pnas.0914009107","volume":"107","author":"SJ Polyak","year":"2010","unstructured":"Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DYW, Liu Y, Graf TN, Oberlies NH. Identification of hepatoprotective flavonolignans from Silymarin. Proc Natl Acad Sci U S A. 2010;107:5995\u20139. https:\/\/doi.org\/10.1073\/pnas.0914009107.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3380_CR12","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/carcin\/bgm069","volume":"28","author":"G Deep","year":"2007","unstructured":"Deep G, Oberlies NH, Kroll DJ, Agarwal R. Isosilybin B and isosilybin A inhibit growth, induce G1 arrest and cause apoptosis in human prostate cancer LNCaP and 22Rv1 cells. Carcinogenesis. 2007;28:1533\u201342. https:\/\/doi.org\/10.1093\/carcin\/bgm069.","journal-title":"Carcinogenesis"},{"key":"3380_CR13","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1002\/fsn3.4010","volume":"12","author":"HM Jaffar","year":"2024","unstructured":"Jaffar HM, Al-Asmari F, Khan FA, Rahim MA, Zongo E, Silymarin. Unveiling its Pharmacological spectrum and therapeutic potential in liver diseases\u2014A comprehensive narrative review. Food Sci Nutr. 2024;12:3097\u2013111. https:\/\/doi.org\/10.1002\/fsn3.4010.","journal-title":"Food Sci Nutr"},{"key":"3380_CR14","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1007\/s10620-018-5268-0","volume":"63","author":"Q Ou","year":"2018","unstructured":"Ou Q, Weng Y, Wang S, Zhao Y, Zhang F, Zhou J, Wu X. Silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the Nf-\u03baB pathway. Dig Dis Sci. 2018;63:3398\u2013408. https:\/\/doi.org\/10.1007\/s10620-018-5268-0.","journal-title":"Dig Dis Sci"},{"key":"3380_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ijc.23485","volume":"123","author":"G Deep","year":"2008","unstructured":"Deep G, Oberlies NH, Kroll DJ, Agarwal R. Identifying the differential effects of Silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells. Int J Cancer. 2008;123:41\u201350. https:\/\/doi.org\/10.1002\/ijc.23485.","journal-title":"Int J Cancer"},{"key":"3380_CR16","doi-asserted-by":"publisher","first-page":"10202","DOI":"10.1111\/jcmm.15634","volume":"24","author":"H Li","year":"2020","unstructured":"Li H, Ma Z, Che Z, Li Q, Fan J, Zhou Z, Wu Y, Jin Y, Liang P, Che X. Comprehensive role of prostate-specific antigen identified with proteomic analysis in prostate cancer. J Cell Mol Med. 2020;24:10202\u201315. https:\/\/doi.org\/10.1111\/jcmm.15634.","journal-title":"J Cell Mol Med"},{"key":"3380_CR17","doi-asserted-by":"publisher","unstructured":"Zappavigna S, Vanacore D, Lama S, Potenza N, Russo A, Ferranti P, Dallio M, Federico A, Loguercio C, Sperlongano P, Caraglia M, Stiuso P. Silybin-Induced apoptosis occurs in parallel to the increase of ceramides synthesis and MiRNAs secretion in human hepatocarcinoma cells. Int J Mol Sci. 2019;20(2190). https:\/\/doi.org\/10.3390\/ijms20092190.","DOI":"10.3390\/ijms20092190"},{"key":"3380_CR18","doi-asserted-by":"publisher","first-page":"180","DOI":"10.4254\/wjh.v15.i2.180","volume":"15","author":"C-Y Zhang","year":"2023","unstructured":"Zhang C-Y, Liu S, Yang M. Antioxidant and anti-inflammatory agents in chronic liver diseases: molecular mechanisms and therapy. World J Hepatol. 2023;15:180\u2013200. https:\/\/doi.org\/10.4254\/wjh.v15.i2.180.","journal-title":"World J Hepatol"},{"key":"3380_CR19","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3390\/molecules24061022","volume":"24","author":"J Vost\u00e1lov\u00e1","year":"2019","unstructured":"Vost\u00e1lov\u00e1 J, Tinkov\u00e1 E, Biedermann D, Kosina P, Ulrichov\u00e1 J. Rajnochov\u00e1 Svobodov\u00e1 A. Skin protective activity of Silymarin and its flavonolignans. Molecules. 2019;24:1022. https:\/\/doi.org\/10.3390\/molecules24061022.","journal-title":"Molecules"},{"key":"3380_CR20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/antiox2040398","volume":"2","author":"K Anthony","year":"2013","unstructured":"Anthony K, Saleh M. Free radical scavenging and antioxidant activities of Silymarin components. Antioxidants. 2013;2:398\u2013407. https:\/\/doi.org\/10.3390\/antiox2040398.","journal-title":"Antioxidants"},{"key":"3380_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.lwt.2015.03.047","volume":"63","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Shen Y, Zhu Y, Xu Z. Assessment of the correlations between reducing power, scavenging DPPH activity and anti-lipid-oxidation capability of phenolic antioxidants. LWT - Food Sci Technol. 2015;63:569\u201374. https:\/\/doi.org\/10.1016\/j.lwt.2015.03.047.","journal-title":"LWT - Food Sci Technol"},{"key":"3380_CR22","doi-asserted-by":"publisher","first-page":"10967","DOI":"10.1038\/s41598-018-29370-1","volume":"8","author":"SS Nazeer","year":"2018","unstructured":"Nazeer SS, Saraswathy A, Shenoy SJ, Jayasree RS. Fluorescence spectroscopy as an efficient tool for staging the degree of liver fibrosis: an in vivo comparison with MRI. Sci Rep. 2018;8:10967. https:\/\/doi.org\/10.1038\/s41598-018-29370-1.","journal-title":"Sci Rep"},{"key":"3380_CR23","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.3748\/wjg.v11.i24.3671","volume":"11","author":"H Gao","year":"2005","unstructured":"Gao H, Zhou Y-W. Anti-lipid peroxidation and protection of liver mitochondria against injuries by Picroside II. World J Gastroenterol. 2005;11:3671\u20134. https:\/\/doi.org\/10.3748\/wjg.v11.i24.3671.","journal-title":"World J Gastroenterol"},{"key":"3380_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tips.2020.12.001","volume":"42","author":"I Semova","year":"2021","unstructured":"Semova I, Biddinger SB. Triglycerides in nonalcoholic fatty liver disease: guilty until proven innocent. Trends Pharmacol Sci. 2021;42:183\u201390. https:\/\/doi.org\/10.1016\/j.tips.2020.12.001.","journal-title":"Trends Pharmacol Sci"},{"key":"3380_CR25","doi-asserted-by":"publisher","first-page":"110250","DOI":"10.1016\/j.cbi.2022.110250","volume":"368","author":"X Liu","year":"2022","unstructured":"Liu X, Hu M, Ye C, Liao L, Ding C, Sun L, Liang J, Chen Y. Isosilybin regulates lipogenesis and fatty acid oxidation via the AMPK\/SREBP-1c\/PPAR\u03b1 pathway. Chem Biol Interact. 2022;368:110250. https:\/\/doi.org\/10.1016\/j.cbi.2022.110250.","journal-title":"Chem Biol Interact"},{"key":"3380_CR26","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1021\/np030163b","volume":"66","author":"DY Lee","year":"2003","unstructured":"Lee DY, Liu Y. Molecular structure and stereochemistry of Silybin A, Silybin B, isosilybin A, and isosilybin B, isolated from Silybum Marianum (milk thistle). J Nat Prod. 2003;66:1171\u20134. https:\/\/doi.org\/10.1021\/np030163b.","journal-title":"J Nat Prod"},{"key":"3380_CR27","doi-asserted-by":"publisher","first-page":"100028","DOI":"10.1016\/j.crchbi.2022.100028","volume":"2","author":"KA Scott","year":"2022","unstructured":"Scott KA, Ropek N, Melillo B, Schreiber SL, Cravatt BF, Vinogradova EV. Stereochemical diversity as a source of discovery in chemical biology. Curr Res Chem Biology. 2022;2:100028. https:\/\/doi.org\/10.1016\/j.crchbi.2022.100028.","journal-title":"Curr Res Chem Biology"},{"key":"3380_CR28","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1124\/dmd.113.052423","volume":"41","author":"H-J Zhu","year":"2013","unstructured":"Zhu H-J, Brinda BJ, Chavin KD, Bernstein HJ, Patrick KS, Markowitz JS. An assessment of pharmacokinetics and antioxidant activity of free Silymarin flavonolignans in healthy volunteers: A dose escalation study. Drug Metab Dispos. 2013;41:1679\u201385. https:\/\/doi.org\/10.1124\/dmd.113.052423.","journal-title":"Drug Metab Dispos"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03380-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03380-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03380-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T19:02:47Z","timestamp":1754679767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03380-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3380"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03380-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1502"}}